pharmaphorum5d
Alnylam soars after drug success, paving way for RNAi era
Alnylam soars after drug success, paving way for RNAi era News Shares in US biotech Alnylam have soared after a late-stage study of its RNA interference drug patisaran met its primary endpoint.
Fierce Biotech9d
Arrowhead finds RNAi kidney disease candidate is well tolerated in phase 1/2 IgAN trial cohort
Arrowhead Pharmaceuticals’ phase 1/2a study has found the company’s investigational RNA interference (RNAi) candidate was ...
RNA-editing protein insights could lead to improved treatment for cancer and autoimmune diseases
A research team led by Rice University's Yang Gao has uncovered new insights into the molecular mechanisms of ADAR1, a ...
KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency
KRRO-110 is the first RNA editing development candidate from Korro’s proprietary OPERA TM platform and is currently being evaluated in the Phase 1/2a REWRITE clinical study for AATD. Dosing of the ...